Last Updated: 27/05/2025
Genetic Variation and Evolution of Artemisinin Resistance
Objectives
With reports of emerging drug resistance signalling a threat to the effectiveness of artemisinin-based drugs and leveraging genetic variation and evolution, the aim of this project is to identify genetic variants associated with changing artemisinin responses and detect early stages of drug resistance before a catastrophic loss of these still effective anti-malarial compounds takes hold.
Harvard T.H. Chan School of Public Health (HSPH), United States
Malaria is one of the biggest killers in the world. The 2010 World Malaria Report estimates that almost 225 million people each year become acutely ill from the disease—and approximately one million will die from malaria. In the absence of an effective malaria vaccine, chemotherapy remains the mainstay for treatment and prevention of the disease. Genetic variability of the most dangerous type of malaria, Plasmodium falciparum, underlies its transmission success and impedes efforts to control disease. Drug resistance to antimalarial drugs such as antifolates and chloroquine has spread from Asia throughout Africa and resistance to second and third line drugs is now commonplace. Using the tools of population genetics and genomics, the “Genetic Variation and Evolution of Artemisinin Resistance” project will expand our fundamental understanding of both the genetic variation of malaria and microbial drug resistance among malaria parasites by confirming artemisinin resistance phenotypes, identify the gene (or genes) involved in artemisinin drug resistance, and validate the candidate gene (or genes) involved in artemisinin resistance. Because the emergence of drug resistance threatens to outpace the development of effective new antimalarial drugs, the development of an early warning system for emerging resistance is an essential component to defeating malaria.
Apr 2013 — Sep 2017
$2.66M
Related Resources
